Particularly, on 5 April 2024, the FDA granted accelerated approval to T-DXd for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors, including NSCLC, who had received prior systemic therapy and lacked satisfactory alternatives. Here, ERBB2 is linked to non-small cell lung carcinoma.